SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.70-0.8%Jan 23 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (10067)5/18/1999 9:14:00 PM
From: Cacaito  Read Replies (1) of 17367
 
Bluegreen, the bugs could be hidden anywhere but if one does not find it, How do you know they are there? or even somewhere?.

Even after many septic patients are dead, and many pieces are taken for bacterial and viral culture and PCR studies done from everywhere in the body an offending agent is not found.

There are accepted clinical definitions of septic shock, and this patients could or could not be included in a trial.

In Xoma's trial the clinical picture is the main entrance to the protocol, not the blood culture, not the cerebrospinal fluid culture.
And even after conclusion they will most probably have to keep those patients in the analysis. Of course breakdown analysis by subgroups are acceptable, better if it was planned ahead, instead of post hoc.

Bluegreen, you are entitled to a break. Each Xoma shareholders need one (I am assuming you are one).

ncbi.nlm.nih.gov

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext